Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25015739 | 0.90 | CYP3A4 (0.38) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25015970 | 0.90 | CYP3A4 (0.38) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25015964 | 0.89 | CNR2 (0.39) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25016295 | 0.88 | USP30 (0.41) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25016100 | 0.88 | USP30 (0.41) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25017943 | 0.87 | ACHE (0.43) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL25015770 | 0.85 | KDM4E (0.49) | ACHE | |
| SCHEMBL21822737 | 0.84 | CTSS (0.42) | — | |
| SCHEMBL31689662 | 0.84 | CTSS (0.42) | — | |
| SCHEMBL28598750 | 0.84 | F10 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | HTR2C 876/4885HTR2A 540/4885CYP1A2 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.